Antimalarials

"Antimalarials" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585)

Descriptor ID	D000962
MeSH Number(s)	D27.505.954.122.250.100.085
Concept/Terms	Antimalarials Antimalarials Antimalarial Agents Agents, Antimalarial Antimalarial Drugs Drugs, Antimalarial Anti-Malarials Anti Malarials

Below are MeSH descriptors whose meaning is more general than "Antimalarials".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Anti-Infective Agents [D27.505.954.122]
Antiparasitic Agents [D27.505.954.122.250]
Antiprotozoal Agents [D27.505.954.122.250.100]
Antimalarials [D27.505.954.122.250.100.085]

Below are MeSH descriptors whose meaning is related to "Antimalarials".

Below are MeSH descriptors whose meaning is more specific than "Antimalarials".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antimalarials" by people in this website by year, and whether "Antimalarials" was a major or minor topic of these publications.

Bar chart showing 108 publications over 25 distinct years, with a maximum of 14 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1999	1	0	1
2000	0	1	1
2002	1	1	2
2003	2	0	2
2005	1	1	2
2006	2	0	2
2009	2	0	2
2010	0	1	1
2011	2	0	2
2012	0	3	3
2013	3	1	4
2014	5	1	6
2015	5	2	7
2016	4	1	5
2017	6	2	8
2018	2	0	2
2019	3	1	4
2020	8	3	11
2021	6	0	6
2022	6	0	6
2023	5	0	5
2024	13	1	14
2025	6	3	9
2026	1	1	2

Below are the most recent publications written about "Antimalarials" by people in Profiles.

Popkin-Hall ZR, Carey-Ewend K, Aghakhanian F, Oriero EC, Seth MD, Kashamuka MM, Ngasala B, Ali IM, Mukomena ES, Mandara CI, Kharabora O, Sendor R, Simkin A, Amambua-Ngwa A, Tshefu A, Fola AA, Ishengoma DS, Bailey JA, Parr JB, Lin JT, Juliano JJ. Population genomics of Plasmodium malariae from 4 African countries. JCI Insight. 2026 Jun 22; 11(12).

View in: PubMed
Connelly SV, Muller JG, Ali M, Ngasala BE, Hassan W, Mohamed B, Thwai KL, Sadler JM, Marglous J, Fola AA, Zacharia A, Shija SJ, Mohammed S, C Msolo D, Said H, Peter EE, Odas M, Rutha IJ, Nwange M, Naire K, Ruybal-Pes?ntez S, Verity R, Crudale R, Goel V, Choloi BB, Bj?rkman A, Bailey JA, Lin JT, Juliano JJ. Artemisinin Partial Resistance Mutations in Zanzibar and Tanzania Suggest Regional Spread and African Origins, 2023. J Infect Dis. 2026 Feb 18; 233(2):e491-e495.

View in: PubMed
Zeleke AJ, Fola AA, Tollefson GA, Niar? K, Leonetti A, Taropawala O, Marglous J, Crudale R, Brhane BG, Assefa A, Kiyuka P, Parr JB, Hailu A, Tegegne MA, Bailey JA. High prevalence and emerging positive association of kelch13 R622I and HRP2-based RDT negativity in Plasmodium falciparum in northern Ethiopia. PLoS Pathog. 2025 Dec; 21(12):e1013771.

View in: PubMed
Gashema P, Jordan A, Saramba E, Wernsman Young N, Iradukunda PG, Karema C, Mazarati JB, Juliano JJ, Bailey JA, Banek K. Understanding Malaria Treatment Adherence in Rwanda: Implications for Artemisinin Resistance. Am J Trop Med Hyg. 2025 Dec 03; 113(6):1279-1288.

View in: PubMed
Martin AC, Sadler JM, Simkin A, Musonda M, Katowa B, Matoba J, Schue J, Simulundu E, Bailey JA, Moss WJ, Juliano JJ, Fola AA. Emergence and Rising Prevalence of Artemisinin Partial Resistance Marker Kelch13 P441L in a Low Malaria Transmission Setting in Southern Zambia. J Infect Dis. 2025 Oct 15; 232(4):918-922.

View in: PubMed
Juliano JJ, Meier-Scherling CPG, Wernsman Young N, Tollefson GA, Connelly SV, Parr JB, Conrad MD, Sadler JM, Hennelly CM, Assefa A, Okell L, Fola AA, Niar? K, Marglous J, Carey-Ewend K, Futila Kyong-Shin R, Gerdes Gyuricza I, Cuomo-Dannenburg G, Ruybal-Pes?ntez S, Watson OJ, Verity R, Bailey JA. Toward Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance with Targeted Sequencing: The "What" and "Why". Am J Trop Med Hyg. 2025 Dec 03; 113(6):1169-1177.

View in: PubMed
Okitwi M, Orena S, Tumwebaze PK, Katairo T, Taremwa Y, Byaruhanga O, Tukwasibwe S, Nsobya SL, Legac J, Bailey JA, Cooper RA, Conrad MD, Rosenthal PJ. Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019-2024. Nat Commun. 2025 Aug 09; 16(1):7353.

View in: PubMed
Rosado J, Fola AA, Cojean S, Sarrasin V, Copp?e R, Bailly J, Zaffaroulah R, Bouzayene A, Cic?ron L, Houz? L, Crudale R, Musset L, Thellier M, Pradines B, Clain J, Bailey JA, Houz? S. Assessment of ex vivo antimalarial drug efficacy in African Plasmodium falciparum parasite isolates, 2016-2023: a genotype-phenotype association study. EBioMedicine. 2025 Aug; 118:105835.

View in: PubMed
Katairo T, Asua V, Nsengimaana B, Tukwasibwe S, Semakuba FD, Wiringilimaana I, Kagurusi BA, Mwubaha C, Nakasaanya J, Garg S, Kiyaga S, Mbabazi M, Kabbale KD, Ayitewala A, Nsobya SL, Kamya MR, Ssewanyana I, Bailey JA, Aranda-D?az A, Rosenthal PJ, Greenhouse B, Briggs J, Conrad MD. Performance of molecular inversion probe DR23K and Paragon MAD4HatTeR Amplicon sequencing panels for detection of Plasmodium falciparum mutations associated with antimalarial drug resistance. Malar J. 2025 Jun 12; 24(1):188.

View in: PubMed
Meier-Scherling CPG, Watson OJ, Asua V, Ghinai I, Katairo T, Garg S, Conrad MD, Rosenthal PJ, Okell LC, Bailey JA. Selection of Plasmodium falciparum kelch13 mutations in Uganda in comparison with southeast Asia: a modelling study. Lancet Microbe. 2025 May; 6(5):101027.

View in: PubMed

People

Explore

Similar Concepts

Top Journals